KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Payables (2016 - 2025)

Ionis Pharmaceuticals has reported Payables over the past 17 years, most recently at $28.1 million for Q4 2025.

  • Quarterly results put Payables at $28.1 million for Q4 2025, down 34.64% from a year ago — trailing twelve months through Dec 2025 was $28.1 million (down 34.64% YoY), and the annual figure for FY2025 was $28.1 million, down 34.64%.
  • Payables for Q4 2025 was $28.1 million at Ionis Pharmaceuticals, up from $14.3 million in the prior quarter.
  • Over the last five years, Payables for IONS hit a ceiling of $43.0 million in Q4 2024 and a floor of $5.6 million in Q3 2023.
  • Median Payables over the past 5 years was $14.5 million (2021), compared with a mean of $16.6 million.
  • Biggest five-year swings in Payables: crashed 72.67% in 2023 and later surged 146.67% in 2025.
  • Ionis Pharmaceuticals' Payables stood at $11.9 million in 2021, then surged by 50.55% to $17.9 million in 2022, then soared by 45.23% to $26.0 million in 2023, then skyrocketed by 65.07% to $43.0 million in 2024, then tumbled by 34.64% to $28.1 million in 2025.
  • The last three reported values for Payables were $28.1 million (Q4 2025), $14.3 million (Q3 2025), and $22.8 million (Q2 2025) per Business Quant data.